Results 141 to 150 of about 1,862 (162)

Addressing phenoconversion: the Achilles' heel of personalized medicine [PDF]

British Journal of Clinical Pharmacology, 2015
Phenoconversion is a phenomenon that converts genotypic extensive metabolizers (EMs) into phenotypic poor metabolizers (PMs) of drugs, thereby modifying their clinical response to that of genotypicPMs. Phenoconversion, usually resulting from nongenetic extrinsic factors, has a significant impact on the analysis and interpretation of genotype‐focused ...
Rashmi Shāh
exaly   +3 more sources

Clinical effects of CYP2D6 phenoconversion in patients with psychosis

Journal of Psychopharmacology
Background: Pharmacogenetics is considered a promising avenue for improving treatment outcomes, yet evidence arguing for the use of pharmacogenetics in the treatment of psychotic disorders is mixed and clinical usefulness is under debate.
Roos Van Westrhenen, Thérèse Van Amelsvoort, Emma De Brabander   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

The theoretical problems of “prodrome” and “phenoconversion” in neurodegeneration

2023
The recognition of and approach to prodromal symptoms, those which manifest before a diagnosis can be ascertained at the bedside, are of increasing interest in neurodegenerative research. A prodrome is conceived of as an early window into a disease, a critical time when putative disease-modifying interventions may be best suited for examination ...
Andrea, Sturchio, Alberto J, Espay
openaire   +2 more sources

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial

Clinical Pharmacology & Therapeutics, 2021
CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of certain medications. The CYP2D6 drug metabolizing enzyme is susceptible to inhibition by concomitant drugs, which can lead to a clinical phenotype that is different from the genotype‐based phenotype, a process referred to as phenoconversion. Phenoconversion is highly
Emily J, Cicali, Amanda L, Elchynski, Kelsey J, Cook, John T, Houder, Cameron D, Thomas, D Max, Smith, Amanda, Elsey, Julie A, Johnson, Larisa H, Cavallari, Kristin, Wiisanen   +9 more
openaire   +2 more sources

FoxO1 is required for high glucose-dependent cardiac fibroblasts into myofibroblast phenoconversion

Cellular Signalling, 2021
In the normal heart, cardiac fibroblasts (CFs) maintain extracellular matrix (ECM) homeostasis, whereas in pathological conditions, such as diabetes mellitus (DM), CFs converse into cardiac myofibroblasts (CMFs) and this CFs phenoconversion increase the synthesis and secretion of ECM proteins, promoting cardiac fibrosis and heart dysfunction.
Guillermo Díaz-Araya, Raúl Vivar, Pablo Aranguiz   +2 more
exaly   +3 more sources

Phenocopy and Phenoconversion: Do they Complicate Association Studies?

Pharmacogenomics, 2012
Current pharmacogenetic focus on genotype A number of clinically relevant drug metabo­ lizing enzymes (DMEs) are expressed poly­ morphically in the population, giving rise to at least three distinct genotypes; extensive metabolizers (EMs), poor metabolizers (PMs) and intermediate metabolizers.
Rashmi R, Shah, Robert L, Smith
openaire   +2 more sources

Mechanical regulation of myofibroblast phenoconversion and collagen contraction

Experimental Cell Research, 2019
Activated fibroblasts promote physiological wound repair following tissue injury. However, dysregulation of fibroblast activation contributes to the development of fibrosis by enhanced production and contraction of collagen-rich extracellular matrix.
Boris, Hinz, Christopher A, McCulloch, Nuno M, Coelho   +2 more
openaire   +2 more sources

Phenoconversion in Pure Autonomic Failure

JAMA Neurology
Importance Pure autonomic failure (PAF) can be the prodromal presentation of Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), although phenoconversion rates and predictors have not been systematically reported ...
Sasivimol Virameteekul, Ilenia Bonini, Nicole Campese, Philipp Mahlknecht, Manuela Tan, Werner Poewe, Alastair J. Noyce, Alessandra Fanciulli, Eduardo de Pablo-Fernández   +8 more
openaire   +1 more source

Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy

Expert Opinion on Drug Metabolism and Toxicology
The prevalence of polypharmacy and the increasing availability of pharmacogenetic information in clinical practice have raised the prospect of data-driven clinical decision-making when addressing the issues of drug-drug interactions and genetic polymorphisms in metabolizing enzymes.
Julia Stingl, Roberto Viviani
exaly   +3 more sources

I01 Unawareness of motor phenoconversion in huntington disease

Journal of Neurology, Neurosurgery & Psychiatry, 2012
Background Unawareness of disease manifestations in neurodegenerative diseases has been defined by Flashman et al 2002 as “pathological unawareness of a neurological or functional deficit” and by Antoine et al 2004 as “the discrepancy between the patient9s self report and the report of a natural caregiver or the clinical rating of a health ...
E McCusker, D Gunn, E Epping, C Loy, J Long, K Radford, J Griffith, J Mills, J Paulsen   +8 more
openaire   +1 more source